

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

McCormick et al.

Serial No. 10/067,893

Filed: 8 February 2002

For: Self Antigen Vaccines for Treating B Cell Lymphomas
and Other Cancers

Patent Art Unit: TBA

Examiner: TBA


REPLY TO NOTICE TO COMPLYAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice mailed 28 February 2002, copy attached hereto, as noted on the transmittal, the instant application is a division of U.S. Ser. No. 09/522,900. A paper copy of the Sequence Listing was filed in the instant application on 8 February 2002. Also filed on 8 February 2002 was a Preliminary Amendment. As noted on page 4 of the Preliminary Amendment, the Examiner is authorized to obtain the CRF of the parent application for use in the instant division thereof.

Accordingly, another CRF need not be filed in the instant application and the requirements of said Notice were satisfied by the initial filing of the application and Preliminary Amendment.

Respectfully submitted,

Dean H. Nakamura
Attorney for Applicants
Reg. No. 33,981Roylance, Abrams, Berdo
& Goodman L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036-2680
(202) 659-9076Dated: 14 March 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/067,893	02/08/2002	Alison A. McCormick	42255

CONFIRMATION NO. 1123

FORMALITIES LETTER



OC000000007549592

001609

ROYLANCE, ABRAMS, BERRO & GOODMAN, L.L.P.
1300 19TH STREET, N.W.
SUITE 600
WASHINGTON, DC 20036

Date Mailed: 02/28/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

